Wang, Min <br/><br/>
Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.  [electronic resource] 

 -  Oncotarget  Jul 2015 
 - 17958-67 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.4641  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Basic Helix-Loop-Helix Transcription Factors--genetics<br/>Biomarkers, Tumor--blood<br/>CD4 Lymphocyte Count<br/>Case-Control Studies<br/>China<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Interferon-gamma--blood<br/>Interleukin-17--blood<br/>Interleukins--blood<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--blood<br/>Neoplasm Staging<br/>Nuclear Receptor Subfamily 1, Group F, Member 3--genetics<br/>Polymerase Chain Reaction<br/>RNA, Messenger--metabolism<br/>Receptors, Aryl Hydrocarbon--genetics<br/>Remission Induction<br/>T-Lymphocyte Subsets--drug effects<br/>Th17 Cells--drug effects<br/>Treatment Outcome<br/>Interleukin-22